Posiflex Wins Taiwan Excellence Award with All-In-One POS and Introduces an Exciting New Line of Kiosks
10.12.2020 04:00:00 EET | Business Wire | Press release
Posiflex Technology, Inc., a global leader in Point of Sale (POS), self-service kiosks, and embedded computing technologies. Posiflex has been focused on product applications of retail market trends and endeavors to improve users’ operational efficiency with cutting edge technology since its foundation in 1984. Posiflex is honored to receive the Taiwan Excellence Award 2021 for its innovative all-in-one Android POS, HS-3314A.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201209005001/en/
Posiflex's HS-3314A Wins Taiwan Excellence Awards 2021 (Photo: Business Wire)
The Ministry of Economic Affairs Taiwan established the Taiwan Excellence Awards in 1993. Eligible candidates are subjected to cover four major aspects of “R&D”, “Design”, “Quality” and “Marketing” to identify outstanding products that offer “Innovative Value” while being “made in Taiwan”. Products that have been selected for the Taiwan Excellence Awards would serve as examples of the domestic industries and be promoted by the government internationally to shape the creative image for Taiwanese businesses.
The HS-3314A series is a 14” Android 9.0 PCAP touch POS system with a built-in printer and designed with the high-performance Rockchip RK3399 platform and various peripherals. Built with unique innovation and a compact body, HS-3314A is equipped with a high-speed, detachable thermal receipt printer. Its innovative screwless and modular design not only makes installation simple and maintenance easy but also allows for a variety of peripherals including a secondary display, MSR, fingerprint sensor, and barcode scanner. The whole system greatly improves retailer operation and work efficiency with space-saving design and reduced downtime.
Not only has Posiflex been building the best POS systems for the retail industry, but it is also in sync with the rapid rise of self-service technology. As the world has been deeply affected by the COVID-19 outbreak, it has unleashed a demand for safety-conscious products such as self-service kiosks. Posiflex introduces the new Mercury EK Series to its sophisticated self-service solutions to help operators succeed with the rising need for the self-service kiosk. Built to be compact and functional, the Mercury EK Series is available in 15” PCAP touch screen in landscape mode while 15.6” & 21.5” touch screens are available in both landscape and portrait mode. Designed with flexibility in mind, the Mercury EK Series can deploy as either countertop or floor-standing as well as customizable with peripherals including NFC/RFID reader, fingerprint sensor, 2D scanner, status indicator, and an EMV payment device. The versatility of the Mercury EK Series allows retailers to customize as their businesses need. They are also engineered for single-user assembly and ease of maintenance, thus reducing costs of deployment and service. With all the flexibility and user-friendly features, the Mercury EK Series can serve as an extension of employees, handling mundane tasks while allowing employees to focus on providing better customer service, therefore creating more demand and business for retailers.
With the award-winning all-in-one POS HS-3314A and the small-footprint kiosk Mercury EK Series, Posiflex provides POS/Kiosk solutions with variety and quality for the retail industry to meet customers’ various demands as well as create exceptional consumer experiences.
About Posiflex Group:
Posiflex has designed and manufactured world-class POS solutions for more than 30 years. Since 2016, the company has acquired KIOSK and Portwell, further expanding into self-service and embedded PC offerings. The global Posiflex Group is in place to provide world-class B2B Serviced IoT solutions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201209005001/en/
Contact information
Posiflex Group Press: Brad Chou, marketing@posiflex.com.tw
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom